- Home
- DBRG vs ANIP Comparison
DBRG vs ANIP Comparison
Compare DBRG & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- ANIP
- Stock Information
- Founded
- DBRG 1991
- ANIP 2001
- Country
- DBRG United States
- ANIP United States
- Employees
- DBRG N/A
- ANIP N/A
- Industry
- DBRG Real Estate Investment Trusts
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- ANIP Health Care
- Exchange
- DBRG Nasdaq
- ANIP Nasdaq
- Market Cap
- DBRG 1.8B
- ANIP 2.0B
- IPO Year
- DBRG 2009
- ANIP N/A
- Fundamental
- Price
- DBRG $12.07
- ANIP $98.54
- Analyst Decision
- DBRG Strong Buy
- ANIP Strong Buy
- Analyst Count
- DBRG 7
- ANIP 9
- Target Price
- DBRG $16.00
- ANIP $86.00
- AVG Volume (30 Days)
- DBRG 1.9M
- ANIP 488.4K
- Earning Date
- DBRG 10-31-2025
- ANIP 11-07-2025
- Dividend Yield
- DBRG 0.32%
- ANIP N/A
- EPS Growth
- DBRG N/A
- ANIP N/A
- EPS
- DBRG N/A
- ANIP N/A
- Revenue
- DBRG $173,540,000.00
- ANIP $747,399,000.00
- Revenue This Year
- DBRG N/A
- ANIP $39.32
- Revenue Next Year
- DBRG $61.97
- ANIP $9.62
- P/E Ratio
- DBRG N/A
- ANIP N/A
- Revenue Growth
- DBRG N/A
- ANIP 38.68
- 52 Week Low
- DBRG $6.41
- ANIP $52.50
- 52 Week High
- DBRG $17.33
- ANIP $99.50
- Technical
- Relative Strength Index (RSI)
- DBRG 64.64
- ANIP 79.27
- Support Level
- DBRG $11.13
- ANIP $96.50
- Resistance Level
- DBRG $11.44
- ANIP $99.50
- Average True Range (ATR)
- DBRG 0.35
- ANIP 2.17
- MACD
- DBRG 0.06
- ANIP -0.31
- Stochastic Oscillator
- DBRG 67.97
- ANIP 90.02
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.